Melisa Hunis¹ and Adrian Hunis²*

¹School of Medicine, Buenos Aires University (UBA)
²School of Medicine, Maimonides University (UMAI) Oncología Integral Belgrano, Buenos Aires, Argentina

*Corresponding Author: Adrian Hunis, School of Medicine, Maimonides University (UMAI) Oncología Integral Belgrano, Buenos Aires, Argentina.

Received: December 03, 2021; Published: January 05, 2022

Abstract

CheckMate-9ER is a phase III, randomized, open label study evaluating patients with previously untreated advanced renal cell carcinoma (CRC).

Keywords: Nivolumab; kidney Cancer; Cabozantinib; Versus

References

1. , et al. “Introduction to Clinical Oncology”. Editorial of the National University of Quilmes I.II (2009).
2. https://ascopubs.org/toc/jco/29/15_suppl
3. “A Study of Nivolumab Combined with Cabozantinib Compared to Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 9ER)”.

Citation

Citation: Melisa Hunis and Adrian Hunis. “Critical Analysis of the Study of Nivolumab with Cabozantinib Versus Sunitinib in Previously Untreated Patients with Advanced or Metastatic kidney Cancer (Check Mate 9ER)" Acta Scientific Cancer Biology 6.1 (2022): 19-22.

Copyright

Copyright: © 2022 Melisa Hunis and Adrian Hunis. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.